Previous close | 37.60 |
Open | 38.20 |
Bid | 38.60 x N/A |
Ask | 39.00 x N/A |
Day's range | 38.20 - 38.20 |
52-week range | 30.00 - 39.20 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Harvey Jones has surprised himself by living up to Warren Buffett's most important investment rule. But is his success down to luck or judgement? The post I’ve just met Warren Buffett’s first rule of investing. Here are 3 ways I did it appeared first on The Motley Fool UK.
The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.
New drugs should significantly boost this FTSE stock’s earnings in my view. But even without them it looked very undervalued to me. The post Is this FTSE growth superstar set to soar even higher on new drug results? appeared first on The Motley Fool UK.